Thursday, March 23, 2023
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Adjunct Assistant Professor of Medicine
Emory University School of Medicine
Atlanta, Georgia
The opinions expressed are those of Dr Isaacs and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Isaacs’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.25 ABIM MOC points
This activity is intended for diabetologists and endocrinologists, primary care physicians, and gastroenterologists.
The goal of this activity is for learners to be better able to assimilate data on emerging treatments for nonalcoholic steatohepatitis (NASH) and determine which patients may be candidates for these therapies.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Adjunct Assistant Professor of Medicine
Emory University School of Medicine
Atlanta, Georgia
The opinions expressed are those of Dr Isaacs and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Isaacs’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC Released: 1/23/2023
Valid for credit through: 1/23/2024
processing....
What is the most common cause of chronic liver disease in the United States? Did you guess "alcohol-related liver disease"? How about "chronic hepatitis C"? At one time, yes, these were the most common causes. But not any longer. The epidemiology of liver disease in the United States has changed.[1] Today, the most common cause of chronic liver disease is nonalcoholic fatty liver disease (NAFLD). And 95% of people with NAFLD do not know they have it.[2]
Medscape recently sat with the world-renowned endocrinologist, educator, and fatty liver disease expert, Scott Isaacs, MD, to explore the alarming rise of NAFLD.
Medscape: What is NAFLD, and how does it impact patients?
Scott Isaacs, MD, FACP, FACE: NAFLD represents a spectrum of fatty liver disease ranging from steatosis to progressive steatosis with inflammation, fibrosis, cirrhosis, and finally, hepatic decompensation (Figure 1).[3] Fueled by the obesity and type 2 diabetes (T2D) epidemics, NAFLD affects approximately 1 in 3 people in the United States.[4] Of them, up to 30% have the more severe form of NAFLD, called nonalcoholic steatohepatitis (NASH).[5] In people with T2D, the prevalence of NASH may exceed 37%.[6] NASH is a risk factor for hepatocellular carcinoma, the leading indication for liver transplant in women, and soon to be the number 1 cause of liver transplant in men.[1,7]
Figure 1. The Spectrum and Progression of NAFLD[4]
But the primary cause of death in people with NAFLD is not liver disease…
Please answer this question to complement your learning experience.
